UCL Frontiers events

1-day meetings to update practising oncologists, GPs, nurses, scientists& researchers about advances in Haematology, Urology, Women’s Health, Lung,& GI oncology

[UCL Frontiers events @ucl_frontiers]

Our chairmen for 'UCL Frontiers of Oncology: Gastrointestinal Oncology' are getting ready to welcome today's first speaker. @uclcancer

[UCL Frontiers events @ucl_frontiers]

TEST - https://t.co/vFoqplKpla

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

We spent yesterday @ucl_frontiers Frontiers of #Gastrointestinal #Oncology meeting - storify here: https://t.co/r48wG7lLSq #frontiersGI

[Healthcare Hashtag Project @healthhashtags]

Top Influencers of #frontiersgi: @lancetgastrohep @ucl_frontiers @uclcancer @thelancetoncol @idibaps More 📊: https://t.co/d6hyoUb01v

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

Closing out the day, Christopher Heeschen on stem cells in #pancreaticcancer #FrontiersGI #pancsm

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

Biomarkers for immunotherapy: PD-1 is weak biomarker; we need to look at surrogates of immune response & mutational burden too #frontiersGI

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

Arkenau: can we switch "immune cold" MMR/MSI proficient tumours to "inflammatory" state treatable with anti-PD-1/PD-L1 drugs? #frontiersGI

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

Tobias Arkenau up next, on immunotherapy for #gastrointestinal #cancer #FrontiersGI

[UCL Frontiers events @ucl_frontiers]

Final speaker: Prof Christopher Heeschen - "Stem cells in GI (pancreas) cancer" @Bartscancer #FrontiersGI https://t.co/QOAU7AxzlV

[UCL Frontiers events @ucl_frontiers]

Our penultimate speaker: "Immunotherapy in GI cancer" from Dr Hendrik-Tobias Arkenau @SarahCannon_UK https://t.co/vUU7ffxzTa #FrontiersGI

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

Next, Nicola Valeri on microRNAs in #gastrointestinal cancers #frontiersGI

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

Hochhauser: we need to better understand interactions between chemo & signal transduction pathways to optimise combo therapy #frontiersGI

[UCL Frontiers events @ucl_frontiers]

Second talk in our last session: "Microrna in Gastrointestinal Cancer" - Dr Nicola Valeri #FrontiersGI @ICR_London https://t.co/GFigHq36Li

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

Kicking off the last session, Daniel Hochhauser on integrating conventional and novel therapies for #gastrointestinal cancers #frontiersGI

[UCL Frontiers events @ucl_frontiers]

Prof Daniel Hochhauser - "Integration of conventional & novel therapies in GI cancer" #FrontiersGI @uclcancer https://t.co/Y5wbR8SSPh

[UCL Frontiers events @ucl_frontiers]

Final Session: "Emerging Strategies for Therapy of Gastrointestinal Cancer" #FrontiersGI @uclcancer @ICR_London @SarahCannon_UK @QMBCI

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

ABC-03 trial of cediranib for biliary tract cancer - https://t.co/RE9xyDIj4I @TheLancetOncol #frontiersGI

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

Up now: Hemant Kocher on #pancreaticcancer - the elephant in the room? #frontiersGI #pancsm

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

Basis of ongoing ph 3, stratified trials in #HCC here: https://t.co/cjt6FOiYbF & https://t.co/TjR6hr2N5g #frontiersGI @TheLancetOncol

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

Llovet: trial enrichment necessary - eg for signalling cascades (eg tivantinib) or biomarkers (eg AFP and ramucirumab) #frontiersGI (1/2)

[UCL Frontiers events @ucl_frontiers]

Onsite today: @PancreaticCanUK who may find current talk of particular interest. Hopefully some good discussion in the next coffee break!